Coloplast A/S (OTCMKTS:CLPBY) Upgraded to Moderate Buy at Royal Bank of Canada

Coloplast A/S (OTCMKTS:CLPBY) was upgraded by Royal Bank of Canada from a “hold” rating to a “moderate buy” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other equities analysts also recently weighed in on the stock. Sanford C. Bernstein upgraded shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 28th. UBS Group raised Coloplast A/S from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, Hsbc Global Res raised shares of Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research report on Monday, November 18th.

Coloplast A/S Stock Up 1.1 %

Coloplast A/S stock opened at $11.10 on Monday. Coloplast A/S has a 1 year low of $10.54 and a 1 year high of $14.34. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.66 and a current ratio of 1.02. The business has a 50-day moving average of $11.11 and a 200-day moving average of $12.26.

Coloplast A/S (OTCMKTS:CLPBY) last announced its quarterly earnings results on Tuesday, February 4th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.01). Coloplast A/S had a net margin of 17.81% and a return on equity of 28.60%. As a group, sell-side analysts expect that Coloplast A/S will post 0.31 EPS for the current year.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.